flupirtine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
1215 56995-20-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • flupirtin maleate
  • flupirtine maleate
  • flupirtine
  • katadolon
  • Molecular weight: 304.33
  • Formula: C15H17FN4O2
  • CLOGP: 3.05
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 3
  • TPSA: 89.27
  • ALOGS: -3.62
  • ROTB: 6

Drug dosage:

DoseUnitRoute
0.40 g O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 28.16 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.60 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.15 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.50 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.350 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.662 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 57.016 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 2.018 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 22.710 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 44.040 % High 1
herg hERG pIC50 4.811 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.227 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.243 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 22.380 % High 1
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK1,JAK2,MAP3K1,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MARK4,MET,MTOR,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK 47
kinase-selectivity-class ACVR2B,AURKA,AXL,DDR1,EPHB4,ERBB2,GRK2,JAK1,MAP3K21,MAPK7,MARK4,SIK2,STK33,TEK,TTK 15
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.361 High 1
mh-clint Mouse hepatocyte intrinsic clearance 6.457 High 1
mppb Mouse plasma protein binding (% unbound) 15.760 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 4.111 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 43.190 % High 1
rh-clint Rat hepatocyte intrinsic clearance 8.128 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 73.090 % High 1
rppb Rat plasma protein binding (% unbound) 20.370 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 83.368 uM High 1

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1986 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug-induced liver injury 117.07 50.89 45 1244 90273 90536885
Nail avulsion 66.04 50.89 10 1279 342 90626816
Paranasal sinus inflammation 60.08 50.89 10 1279 629 90626529
Defaecation disorder 56.34 50.89 10 1279 919 90626239

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug-induced liver injury 210.25 67.51 53 316 120014 110468916

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N02BG07 NERVOUS SYSTEM
ANALGESICS
OTHER ANALGESICS AND ANTIPYRETICS
Other analgesics and antipyretics
MeSH PA D000700 Analgesics
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents

Related Drugs by ATC class:

N02BG Other analgesics and antipyretics 8 drugs
floctafenineglafeninemethoxyfluranenabiximolsnefopamrimazoliumviminolziconotide

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.83 acidic
pKa2 7.26 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Potassium voltage-gated channel subfamily KQT member 2 Ion channel ACTIVATOR EC50 5 IUPHAR
Potassium voltage-gated channel subfamily KQT member 3 Ion channel WOMBAT-PK
Serine hydroxymethyltransferase, mitochondrial Enzyme IC50 6.03 CHEMBL

External reference:

IDSource
4025785 VUID
N0000179138 NUI
D07978 KEGG_DRUG
75507-68-5 SECONDARY_CAS_RN
4025785 VANDF
4025786 VANDF
C0060583 UMLSCUI
CHEBI:94646 CHEBI
CHEMBL255044 ChEMBL_ID
CHEMBL1256752 ChEMBL_ID
DB06623 DRUGBANK_ID
C034161 MESH_SUPPLEMENTAL_RECORD_UI
53276 PUBCHEM_CID
2598 IUPHAR_LIGAND_ID
3976 INN_ID
MOH3ET196H UNII
236774 RXNORM
006784 NDDF
006785 NDDF
1000791000202109 SNOMEDCT_US

Pharmaceutical products:

None